Best Penny Stocks Under 5 Cents Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.05 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.05.

Show:
Sintx Technologies stock logo

#1 - Sintx Technologies

NASDAQ:SINT
Stock Price:
$0.04
P/E Ratio:
-0.01
Market Cap:
$916,000.00
Average Trading Volume:
22.16 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Gamida Cell stock logo

#2 - Gamida Cell

NASDAQ:GMDA
Stock Price:
$0.02
P/E Ratio:
-0.03
Market Cap:
$2.77 million
Average Trading Volume:
9.20 million shares
Consensus Rating:
Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.75 (26,288.9% Upside)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Better Therapeutics stock logo

#3 - Better Therapeutics

NASDAQ:BTTX
Stock Price:
$0.01
P/E Ratio:
-0.01
Market Cap:
$449,000.00
Average Trading Volume:
5.27 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$6.00 (66,566.7% Upside)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Evofem Biosciences stock logo

#4 - Evofem Biosciences

NASDAQ:EVFM
Stock Price:
$0.02
P/E Ratio:
0.00
Market Cap:
$929,000.00
Average Trading Volume:
778,788 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Invitae stock logo

#5 - Invitae

NYSE:NVTA
Stock Price:
$0.00 (-$0.01)
P/E Ratio:
0.00
Market Cap:
$134,000.00
Average Trading Volume:
23.72 million shares
Consensus Rating:
Strong Sell (0 Buy Ratings, 0 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$1.00 (199,900.0% Upside)
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Meyer Burger Technology stock logo

#6 - Meyer Burger Technology

OTCMKTS:MYBUF
Stock Price:
$0.02 (+$0.00)
Average Trading Volume:
335,705 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Meyer Burger Technology AG, a technology company, produces and sells solar cells and modules. It operates through Photovoltaics and Modules segments. The company offers its products based on proprietary Heterojunction/SmartWire technologies. It operates in Germany, Switzerland, rest of Europe, Asia, the United States, and internationally. Meyer Burger Technology AG was founded in 1953 and is headquartered in Thun, Switzerland.
Movella stock logo

#7 - Movella

NASDAQ:MVLA
Stock Price:
$0.03
Market Cap:
$1.32 million
Average Trading Volume:
186,161 shares
Consensus Rating:
Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.45 (9,323.1% Upside)
Movella Holdings Inc. operates as a full-stack provider of sensors, software, and analytics that enable the digitization of movement in the United States. Its real-time character movement in digital environments transforms movement into digital data that provides actionable insights. The company offers Xsens 3D Body Motion Systems comprises wearable sensor systems and motion capture solutions, including MVN Animate or MVN Analyze software, a full-body wearable sensor system, which captures the motion of the human body. It also provides Xsens sensor modules that enables customers to accelerate the development of motion-based applications; and DOT wearables for analysis and reporting of human kinematics. In addition, the company offers Kinduct human performance platform that provides biomechanical, biometric, and objective data for athletic performance, wellness, and injury risk. It serves the entertainment, health and sports, and automation and mobility markets. Movella Holdings Inc. is based in Henderson, Nevada.
MetaWorks Platforms stock logo

#8 - MetaWorks Platforms

OTCMKTS:MWRK
Stock Price:
$0.02
Market Cap:
$1.87 million
Average Trading Volume:
107,490 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
MetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.
Evelo Biosciences stock logo

#9 - Evelo Biosciences

NASDAQ:EVLO
Stock Price:
$0.05
P/E Ratio:
0.00
Market Cap:
$940,000.00
Average Trading Volume:
40,657 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

#10 - SQZ Biotechnologies

OTCMKTS:SQZB
Stock Price:
$0.05
P/E Ratio:
-0.02
Market Cap:
$1.37 million
Average Trading Volume:
33,690 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Labrador Iron Mines stock logo

#11 - Labrador Iron Mines

OTCMKTS:LBRMF
Stock Price:
$0.04
Average Trading Volume:
21,192 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Labrador Iron Mines Holdings Limited, a mineral resource company, engages in the exploration, development, and mining of iron ore projects in Canada. Its flagship project is the Houston project, which is an open pit direct shipping iron ore project located near the town of Schefferville. The company was incorporated in 2007 and is headquartered in Toronto, Canada.
Eguana Technologies stock logo

#12 - Eguana Technologies

OTCMKTS:EGTYF
Stock Price:
$0.01
Average Trading Volume:
65,270 shares
Consensus Rating:
Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.90 (9,900.0% Upside)
Eguana Technologies Inc. designs and manufactures residential and commercial energy storage systems for fuel cell, photovoltaic, and battery applications in Canada, Asia, Australia, Europe, and the United States. The company provides its products under the Enduro, Evolve, and Elevate brand names. The company was formerly known as Sustainable Energy Technologies Ltd. and changed its name to Eguana Technologies Inc. in September 2013. Eguana Technologies Inc. is headquartered in Calgary, Canada.
Novan stock logo

#13 - Novan

NASDAQ:NOVN
Stock Price:
$0.00
P/E Ratio:
0.00
Market Cap:
$22,000.00
Average Trading Volume:
602,421 shares
Consensus Rating:
Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
Horizonte Minerals stock logo

#14 - Horizonte Minerals

OTCMKTS:HZMMF
Stock Price:
$0.01
Average Trading Volume:
61,830 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Horizonte Minerals Plc, together with its subsidiaries, engages in the exploration and development of mineral projects in Brazil. The company primarily explores for nickel deposits, as well as cobalt deposits. It holds 100% interest in the Araguaia ferronickel; and the Vermelho Nickel-Cobalt project in the eastern part of the Carajás mining district. The company is headquartered in London, the United Kingdom.
PT Sarana Menara Nusantara Tbk. stock logo

#15 - PT Sarana Menara Nusantara Tbk.

OTCMKTS:SMNUF
Stock Price:
$0.03
P/E Ratio:
0.00
Average Trading Volume:
6,367 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
PT Sarana Menara Nusantara Tbk. owns and operates telecommunication towers for wireless operators in Indonesia. It operates through two segments, Tower Rental, and Other Services. The company offers wireline telecommunication services to provide internet broadband and virtual private network; fiber to the home (FTTH) telecommunication services to build and manage fiber optic infrastructure; and very small aperture terminal (VSAT) solution to facilitate telecommunication services using satellite technology to remote locations. It also offers telecommunication equipment trading, construction, and installation services; system communication data, internet interconnection, satellite telecommunication, payment, hosting and related services. In addition, the company owns and rents real estate properties; trades in various goods; and wholesales and retails computer and computer equipment. Further, it engages in the management consulting; electrical power support; and electric power generation activities. The company was founded in 2008 and is headquartered in Kudus, Indonesia. PT Sarana Menara Nusantara Tbk. is a subsidiary of PT Sapta Adhikari Investama.
Kaspien stock logo

#16 - Kaspien

NASDAQ:KSPN
Stock Price:
$0.01
P/E Ratio:
0.00
Market Cap:
$40,000.00
Average Trading Volume:
18,643 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kaspien Holdings Inc. operates an e-commerce services provider. Its platform of software and services enable brand's online distribution channel on digital marketplaces, such as Amazon, Walmart, Target, and others. The company's technology-enabled retailer that delivers brand partners across Amazon.com US, Amazon.com Canada, Target.com, and Walmart.com online marketplaces. The company was formerly known as Trans World Entertainment Corporation and changed its name to Kaspien Holdings Inc. in September 2020. Kaspien Holdings Inc. was incorporated in 1972 and is headquartered in Spokane, Washington.
Anaergia stock logo

#17 - Anaergia

OTCMKTS:ANRGF
Stock Price:
$0.01
P/E Ratio:
-0.04
Market Cap:
$311,000.00
Average Trading Volume:
12,081 shares
Consensus Rating:
Reduce (0 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
N/A
Anaergia Inc., together with its subsidiaries, provides solutions for the generation of renewable energy and conversion of waste to resources. The company offers anaerobic digestion technologies for the production of clean energy, fertilizers, and recycled water from waste streams. It offers wastewater resource recovery, municipal solid waste, and agri-food solutions. Anaergia Inc. was founded in 2007 and is headquartered in Burlington, Canada.
LZG International stock logo

#18 - LZG International

OTCMKTS:LZGI
Stock Price:
$0.03
Market Cap:
$5.69 million
Average Trading Volume:
2,281 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.00 (15,284.6% Upside)
LZG International, Inc. operates as an artificial intelligence (AI) solutions company. The company offers AI solutions to empower the enterprise stars of tomorrow. Its technologies and advanced data services transform continuous learning, narrative reasoning, language models, and cloud and blockchain technologies into auditable, explainable, and easy to integrate AI solutions. The company was formerly known as LazyGrocer.Com, Inc. and changed its name to LZG International, Inc. in August 2009. LZG International, Inc. was incorporated in 2000 and is based in New York, New York. As of March 14, 2024, LZG International, Inc. operates as a subsidiary of Genius Group Limited.
SIGNA Sports United stock logo

#19 - SIGNA Sports United

NYSE:SSU
Stock Price:
$0.00
Market Cap:
$78,000.00
Average Trading Volume:
214,531 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.90 (949,900.0% Upside)
SIGNA Sports United N.V. operates online sports web shops in the European Union, Switzerland, Norway, the United Kingdom, and the United States. Its product categories include bike, tennis/racket sports, outdoor, and team sports and athleisure. The company is headquartered in Berlin, Germany.
Sonic Foundry stock logo

#20 - Sonic Foundry

NASDAQ:SOFO
Stock Price:
$0.00
P/E Ratio:
0.00
Market Cap:
$4,000.00
Average Trading Volume:
32,657 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Sonic Foundry, Inc. provides video capture, management, and streaming solutions in the United States, Europe, the Middle East, Asia, and internationally. The company offers Video Capture solutions, including Mediasite Recorder and Recorder Pro that are built-in room appliances used in schedule-based capture and advanced audio/video integration; Mediasite Mobile Recorders, a portable recording device used to capture and stream broadcast-quality video; Mediasite Mosaic & Mosaic Pro that allows instructors, employees, and students to create videos, screencasts, and slideshows from their computers or mobile devices; and Mediasite Capture, a browser-based recording application that provides users a quick way to record their camera, microphone, and desktop. It also provides Video Management and Delivery solutions to manage, search, analyze, publish, and stream video content; Vidable, an AI powered solution that turns an organization's video libraries into dynamic knowledge base; Global Learning Exchange that provides students to access higher education in a flexible, cost effective, and locally supported environment; and Mediasite Cloud, a Software as a Service solution to host and manage customers' content. It markets its products to educational institutions, corporations, and government entities through reseller networks, direct sales, and partnerships with system integrators. Sonic Foundry, Inc. was founded in 1991 and is headquartered in Madison, Wisconsin.
Aravive stock logo

#21 - Aravive

NASDAQ:ARAV
Stock Price:
$0.04
P/E Ratio:
-0.04
Market Cap:
$2.95 million
Consensus Rating:
Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$13.50 (33,565.8% Upside)
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

#22 - Sierra Rutile

OTCMKTS:SRRHF
Stock Price:
$0.03
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Sierra Rutile Holdings Limited engages in the multi-deposit mineral sands mining operations in Asia, Europe, the United States, Africa, and the Middle East. It produces, refines, and sells rutile, ilmenite, zircon, and other concentrates. The company holds a 100% interest in the Sembehun project located in Moyamba district in Sierra Leone. Its products are used in paints, laminates, plastic pipes and packaging, inks, clothing, sunscreen, toothpaste, and the cosmetic industry, as well as aeronautics, medical implants, defense, and sporting goods applications. The company was incorporated in 2016 and is based in Perth, Australia.

More Stock Ideas from MarketBeat